BRPI0909997A2 - r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino - Google Patents

r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino

Info

Publication number
BRPI0909997A2
BRPI0909997A2 BRPI0909997A BRPI0909997A BRPI0909997A2 BR PI0909997 A2 BRPI0909997 A2 BR PI0909997A2 BR PI0909997 A BRPI0909997 A BR PI0909997A BR PI0909997 A BRPI0909997 A BR PI0909997A BR PI0909997 A2 BRPI0909997 A2 BR PI0909997A2
Authority
BR
Brazil
Prior art keywords
propargyl
crystalline
aminoindane
aminoindan
pharmaceutical composition
Prior art date
Application number
BRPI0909997A
Other languages
English (en)
Portuguese (pt)
Inventor
Anton Frenkel
Ronen Ben-David
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0909997A2 publication Critical patent/BRPI0909997A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0909997A 2008-06-19 2009-06-19 r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino BRPI0909997A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248708P 2008-06-19 2008-06-19
PCT/US2009/003670 WO2009154777A2 (fr) 2008-06-19 2009-06-19 Processus de préparation et de séchage de rasagiline base solide

Publications (1)

Publication Number Publication Date
BRPI0909997A2 true BRPI0909997A2 (pt) 2015-10-27

Family

ID=41431882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909997A BRPI0909997A2 (pt) 2008-06-19 2009-06-19 r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino

Country Status (13)

Country Link
US (2) US7968749B2 (fr)
EP (1) EP2299992A4 (fr)
JP (1) JP2011524907A (fr)
CN (1) CN102065853A (fr)
AU (1) AU2009260728B2 (fr)
BR (1) BRPI0909997A2 (fr)
CA (1) CA2727017A1 (fr)
EA (1) EA021472B1 (fr)
IL (1) IL209134A0 (fr)
MX (1) MX2010013875A (fr)
NZ (1) NZ589547A (fr)
WO (1) WO2009154777A2 (fr)
ZA (1) ZA201008755B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (fr) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Dosages pharmaceutiques contenant de la rasagiline
US20090111892A1 (en) * 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CA2646250A1 (fr) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Utilisation de rasagiline pour le traitement du syndrome des jambes sans repos
EP1892233A1 (fr) 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
ZA200903903B (en) * 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (fr) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate d'un sel de rasagiline en combinaison avec un agent inactive soluble dans l'eau
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20090181086A1 (en) * 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009151594A1 (fr) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Capsules molles de rasagiline
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
ES2608782T3 (es) * 2010-04-30 2017-04-17 Teikoku Pharma Usa, Inc. Composiciones transdérmicas de propinilaminoindano
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
CA2806740A1 (fr) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Utilisation de rasagiline pour le traitement d'un trouble olfactif
WO2013055687A2 (fr) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindane
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
EA201491734A1 (ru) 2012-03-21 2015-01-30 Синтон Бв Стабилизированные фармацевтические композиции, содержащие соли разагилина
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
BR112015003520B1 (pt) * 2012-08-31 2020-10-13 Sumitomo Chemical Company, Limited método para a produção de (r)-1,1,3-trimetil-4-aminoindano
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
US9151660B2 (en) * 2013-05-22 2015-10-06 Professional Compounding Centers Of America (Pcca) Method for validation of pharmaceutical formulation composition weight

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
WO2006014973A2 (fr) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Dosages pharmaceutiques contenant de la rasagiline
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
CA2901244A1 (fr) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Preparations de rasagiline presentant une uniformite de teneur amelioree
EP1954667B1 (fr) * 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Procedes de separation d amino-indanes propargyles
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CA2646250A1 (fr) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Utilisation de rasagiline pour le traitement du syndrome des jambes sans repos
JP4989153B2 (ja) * 2006-08-15 2012-08-01 コスモ石油株式会社 ５−アミノレブリン酸リン酸塩の新規結晶及びその製造方法
EP1892233A1 (fr) 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
JP5356248B2 (ja) 2006-12-14 2013-12-04 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンのタンニン酸塩
ZA200903903B (en) 2006-12-14 2010-08-25 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (fr) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate d'un sel de rasagiline en combinaison avec un agent inactive soluble dans l'eau
AU2008296908B2 (en) 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CA2708820C (fr) 2007-12-24 2016-05-10 Cipla Limited Procede de synthese de derives d'aminoindane propargyles
US20090181086A1 (en) 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009122301A2 (fr) 2008-03-31 2009-10-08 Actavis Group Ptc Ehf Particules de mésylate de rasagiline et leur procédé de préparation
WO2009151594A1 (fr) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Capsules molles de rasagiline
JP2011522892A (ja) 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
AU2009260733B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CN101606923B (zh) 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
EA201170181A1 (ru) 2008-07-11 2011-08-30 Синтон Бв Полиморфные формы разагилина гидрохлорида
WO2010007181A2 (fr) 2008-07-18 2010-01-21 Medichem, S.A. Nouvelles formes de sels d’un dérivé d’aminoindane
US20100029987A1 (en) 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
AU2009275665A1 (en) 2008-07-30 2010-02-04 Generics [Uk] Limited Polymorphic form of rasagiline mesylate
EP2181980A1 (fr) 2008-10-28 2010-05-05 Chemo Ibérica, S.A. Procédé pour la préparation de (R)-1-aminoindanes
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
US20110015274A1 (en) 2009-07-20 2011-01-20 Ester Masllorens Llinas Form of an aminoindan mesylate derivative
WO2011010324A1 (fr) 2009-07-23 2011-01-27 Alkem Laboratories Ltd. Compositions pharmaceutiques orales stables comprenant de la rasagiline et procédé
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan

Also Published As

Publication number Publication date
NZ589547A (en) 2013-03-28
US20110281953A1 (en) 2011-11-17
US7968749B2 (en) 2011-06-28
AU2009260728A1 (en) 2009-12-23
AU2009260728B2 (en) 2015-01-29
WO2009154777A3 (fr) 2010-05-06
EA021472B1 (ru) 2015-06-30
CA2727017A1 (fr) 2009-12-23
CN102065853A (zh) 2011-05-18
WO2009154777A4 (fr) 2010-07-01
WO2009154777A9 (fr) 2011-01-27
US20090318564A1 (en) 2009-12-24
JP2011524907A (ja) 2011-09-08
US8163960B2 (en) 2012-04-24
WO2009154777A2 (fr) 2009-12-23
EP2299992A2 (fr) 2011-03-30
IL209134A0 (en) 2011-01-31
MX2010013875A (es) 2011-01-20
EP2299992A4 (fr) 2015-10-21
ZA201008755B (en) 2012-02-29
EA201170053A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
BRPI0909997A2 (pt) r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0812064A2 (pt) Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica
BRPI0600795B8 (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BRPI0817423A2 (pt) Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto
CL2007003264A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn
CL2007003263A1 (es) Compuestos derivados de 1,4-benzotiepina 1,1-dioxido; producto farmaceutico; procedimiento de preparacion; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, e
BRPI0922774B8 (pt) composto cloridrato de nelmefeno di-hidratado, sua composição farmacêutica e processos de obtenção e produção dos mesmos.
BRPI0910758A2 (pt) composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto
BRPI0818541A2 (pt) Processo para a produção de um produto farmacêutico
BRPI0607423A2 (pt) forma microcristalina de um composto, processo para a preparação da mesma, uso de uma forma microcristalina, composição farmacêutica e processo para a preparação da mesma, e, produto
IL204052A (en) Annotation of 1,1,1 - Tripluoro - 2 - Hydroxy - 3 - Phenylpropane
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
AP3024A (en) New Diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
BR112012023912A2 (pt) produto de artigos de confeitaria contendo componentes ativos e/ou reativos e métodos de produção do mesmo
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
WO2010049449A3 (fr) Nouveaux sels de sunitinib
IL200128A0 (en) New tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them
EP2412386A4 (fr) Composition empêchant l'adhésion, préparation solide et procédé de production de celles-ci
BRPI0811548A2 (pt) Forma polimórfica de um composto, composição farmacêutica, e, processo para sintetizar uma forma polimórfica de um composto
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"
WO2010079045A3 (fr) Nouveaux sels
BRPI0821454A2 (pt) Formulação farmacêutica, excipiente para a preparação de formulação farmacêuticas de liberação lenta, e, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica.
EP2562156A4 (fr) Dérivés de colchicine ou leurs sels pharmaceutiquement acceptables, procédé pour la préparation desdits dérivés, et composition pharmaceutique comportant lesdits dérivés
BRPI0821076A2 (pt) Processo para a produção de composição de polipropileno colorido tendo um teor elevado de modificação beta

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/132,487 DE 19/06/2008 REIVINDICADA NO PCT/US2009/003670, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E TER APRESENTADO COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 29/03/2011; CONTUDO, O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 14/02/2011 (60 DIAS APOS A ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISPOSICOES PREVISTAS NA LEI 9

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.